Immune checkpoint inhibitors (ICIs), particularly anti-PD-1/PD-L1 monoclonal antibodies such as nivolumab and pembrolizumab, have significantly transformed the therapeutic landscape of advanced non-small cell lung cancer (NSCLC), as demonstrated in landmark Phase III clinical trials. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.